Ribo Newsroom
-
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AIRibo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AIMay 12, 2026 -
Ribo Advances Clinical Development of FXI siRNA vortosiran with EMA Phase 2b CTA Submission in Venous Thromboembolism, ORBIT-FXI-VTERibo has submitted a Phase 2b CTA to the EMA for vortosiran (RBD4059) to prevent venous thromboembolism.May 11, 2026 -
Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)May 6, 2026 -
Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillationRibo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillationApril 14, 2026 -
Ribo Appoints CMO and CBO to Empower Global R&D and PartnershipsRibo Appoints CMO and CBO to Empower Global R&D and PartnershipsMarch 26, 2026 -
Ribo expands beyond the liver with RiboPepSTAR? – enabling targeted siRNA delivery to multiple organsRibo expands beyond the liver with RiboPepSTAR? – enabling targeted siRNA delivery to multiple organsMarch 20, 2026